Blueprint Medicines Q4 2024 Earnings Report

Key Takeaways

Blueprint Medicines reported strong revenue growth in Q4 2024, driven by AYVAKIT sales, which more than doubled YoY. The company significantly reduced its net loss and improved operating margins.

Total Revenue

$146M

Previous year: $72M

+103.4%

EPS

-$0.79

Previous year: -$1.82

-56.6%

Operating Margin

-28.1%

Previous year: -146.1%

-80.8%

Gross Profit Margin

94.9%

R&D Expenses

$83.7M

Previous year: $97.5M

-14.2%

Cash and Equivalents

$864M

Previous year: $711M

+21.6%

Total Assets

$1.18B

Previous year: $1.05B

+12.4%

Blueprint Medicines Revenue

Blueprint Medicines EPS

Blueprint Medicines Revenue by Segment

Blueprint Medicines Revenue by Geographic Location

Forward Guidance

Blueprint Medicines expects continued strong revenue growth in 2025, with AYVAKIT sales driving a projected 45% YoY increase. The company plans to advance its BLU-808 clinical trials and further expand its systemic mastocytosis franchise.

Positive Outlook

Projected revenue growth of 45% YoY in 2025.
AYVAKIT expected to reach $2B in revenue by 2030.
Expansion of BLU-808 trials for allergic and inflammatory diseases.
Further reduction in cash burn expected in 2025.
Strong cash position to support strategic investments.

Challenges Ahead

Net loss persists despite improved financial performance.
High R&D and SG&A expenses remain a challenge.
Continued reliance on AYVAKIT for revenue growth.
Uncertainty around BLU-808 regulatory approvals.
Potential competition in the systemic mastocytosis market.